More and more countries are relying on the medical effects of cannabis. As such, cannabis cultivation in these countries is needed. There are very important markets in the world such as Germany and Holland. The medical cannabis industry is far from reaching its maximum potential. Nowadays, cannabis growers are largely judged on how potent their products are and how much THC their buds contain.
Shifting laws in the regulation of medical cannabis in Uruguay
The Senate approved the law for the promotion, use and access to medical and recreational cannabis in Uruguay. Alejandro Zavala, deputy of that grouping, explained the multiple advantages that the law supposes.
Contributing original content and curating quality information on only the most promising cannabis companies and the most influential investors, Hemp.im allows you to save time as you stay on top of the latest trends in this dynamic industry of cannabis.
Government aims to regulate the market for cannabis in Uruguay
One of the main points of the law is to regulate the market for medical cannabis in Uruguay and its by-products, such as oil and extracts. According to Alejandro Zavala, this will be an important change.
“With medical cannabis, we are concerned about one important thing which is the population’s access. Cannabis is not good for every disease; it works for some pathologies, while for others, it is still being studied,” said Zavala.
“People buy cannabis products, they don’t know what’s in it, and they take it. Sometimes it does them good and sometimes it doesn’t. So older people come to the clinic in an emergency with panic attacks because they took something with a lot of THC and they are not used to it. The cannabinol system that we humans have is very complex, and THC, the psychoactive part of cannabis, is one of the components. For example, if you want to treat diseases that have to do with seizures, like refractory epilepsy, there are a lot of ailments related to those kinds of pathologies that are helped by another component of cannabis, not THC,” he explained.
Cannabis in Uruguay has quality standards
There are people with various pathologies who may take one component of cannabis, but not another, or need different proportions. People want cannabis in Uruguay to be prescribed by the doctor, go to the pharmacy and get it done.
If there is no one who can give it to you, who can indicate it to you and tell you what is best for you according to your case, and who can also follow your evolution, it doesn’t make sense.
For this reason, Zavala valued that “the law structures everything because it goes from the regulation of the irregular market that we have.”
The production will have quality standards that will allow the doctor to know what is indicated, and on the other hand, it is important that access to this has a reasonable price. In the law, we propose that the comprehensive health law integrate it, as happens with other benefits.
The exploited cannabis market
Another interesting side that opens with the search for access to different alternatives to medical cannabis is the immense market that this world offers.
“There is also an industry component, and it doesn’t make sense that Uruguay can’t have access to that,” said the congressman. “It cannot be Uruguay, which has a worldwide trademark with the subject of cannabis for recreational legalization and so on, which generates a symbolic reaction to the outside of the country, I do not have today what Canada has, for example. I am referring to a niche market for medicinal cannabis in Uruguay.”
Investors wish to include Uruguay in cannabis markets overseas
There are very important markets in the world like Germany and Holland. There is a lot of money around that industry.
Investors want to involve Uruguayan work and a law that stimulates and promotes them. Here opens a sale of opportunity for cannabis in Uruguay in the diversification of its exports.
A very important industry is being born in the world, which is the use of cannabis in the medical world, and we have scientists, legalized cannabis, and we have patients to study.
(Featured image by Greta Schölderle Møller via Unsplash)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in La República, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Comments are closed for this post.